Benefits
Colonic butyrate delivery vs free butyrate (SHIME®)
In a Triple-L-SHIME® gut simulation model using 3 healthy donor microbiomes, the capsule formulation was 40.9% hydrolyzed in the small intestine with 59.1% reaching the colon (softgel: 48.7% / 51.3%). By contrast, free butyrate (sodium butyrate) is rapidly absorbed in the upper GI and very little reaches the colon — the underlying rationale for using a triglyceride prodrug instead of free butyrate.
Microbiome and inflammation effects (in vitro)
In the same Triple-L-SHIME® + Caco-2/THP1 co-culture model, daily tributyrin increased butyrate production, enriched butyrate-producer bacteria including Faecalibacterium prausnitzii and Anaerostipes, increased IL-10, decreased TNF-α, and protected against inflammation-induced intestinal barrier disruption. Effects emerged later in the treatment period, suggesting longer-term administration matters. All findings are in vitro — human translation is not yet established.
Postbiotic concept
Per the ISAPP definition, tributyrin qualifies as a postbiotic — directly delivering a beneficial bacterial fermentation metabolite (butyrate) without requiring a fiber substrate or live bacteria. Useful framing for individuals with low fiber tolerance or low microbial diversity who can't reliably ferment fiber to butyrate themselves.
Colonocyte energy substrate
Butyrate is the primary energy source for colonocytes, supplying 60-70% of their energy needs. Adequate colonic butyrate supports normal colonic epithelial cell function. Whether oral tributyrin meaningfully increases colonocyte butyrate availability in humans has not been demonstrated in clinical trials.
Stomach-acid resistance and odorless formulation
The triglyceride form resists gastric acid degradation and is odorless — addressing two practical limitations of free butyrate (sodium butyrate has an unpleasant odor and is degraded/absorbed before reaching the colon). Formulation advantage rather than efficacy claim.
Mechanism of action
Pancreatic lipase hydrolysis to colonic butyrate
The triglyceride structure resists gastric acidity. Pancreatic lipase in the small intestine hydrolyzes tributyrin to release butyrate progressively, allowing a portion to reach the colon. This is the distinguishing pharmacokinetic advantage over free butyrate salts.
HDAC inhibition by butyrate
Butyrate inhibits histone deacetylases (HDACs), modifying gene expression with anti-inflammatory and preclinically demonstrated anti-tumor effects in colorectal models. The HDAC mechanism applies to butyrate generally — not specific to tributyrin.
Tight junction integrity and NF-κB anti-inflammatory effects
Butyrate enhances tight junction protein expression (claudins, occludin, ZO-1) in intestinal epithelium and downregulates NF-κB-mediated inflammation, with corresponding effects reported in Caco-2/THP1 co-cultures.
GPR41 / GPR43 short-chain fatty acid receptor activation
Butyrate activates GPR41 (FFAR3) and GPR43 (FFAR2) on enteroendocrine cells, immune cells, and adipocytes — modulating GLP-1, PYY release, and immune signaling. Standard butyrate biology applicable via tributyrin.
Clinical trials
Frontiers in, doi:10.3389/fnut.2025.1712993.
Clinical population described in trial publication.
Frontiers in, doi:10.3389/fnut.2025.1712993. Upper GI tract simulation + Triple-L-SHIME® gut model with 3 healthy donor microbiomes + Caco-2/THP1 co-cultures. Capsule (300 mg) and softgel (450 mg) CoreBiome® formulations. Capsule: 40.9% small-intestinal hydrolysis, 59.1% colonic delivery. Softgel: 48.7% / 51.3%. Increased butyrate, enriched F. prausnitzii and Anaerostipes, increased IL-10, decreased TNF-α, protection from inflammation-induced barrier disruption. In vitro evidence — pivotal for the ingredient but not human.
Florida State University randomized triple-masked crossover trial, planned 300 mg/day CoreBiome® for 4 weeks in sedentary adults with outcomes including metabolite concentrations, gut permeability, inflammation, sleep, and performance.
Clinical population described in trial publication.
Florida State University randomized triple-masked crossover trial, planned 300 mg/day CoreBiome® for 4 weeks in sedentary adults with outcomes including metabolite concentrations, gut permeability, inflammation, sleep, and performance. Trial was terminated due to loss of funding — no outcome data was published. This was the only registered human clinical trial of CoreBiome®.
Clinical evidence on Tributyrin (CoreBiome® Butyrate Prodrug) for the indications and outcomes described.
Clinical population described in trial publication.
Heidor R et al. 2012, Curr Drug Targets 13:1720-1729. Review of tributyrin anticarcinogenic actions focused on colorectal cancer prevention. Preclinical only — animal models and cell lines. No human cancer prevention trials of tributyrin have been conducted.